非小细胞肺癌二线治疗的进展

doi:10.3760/cma.j.issn.1673422X.2015.05.018

国际肿瘤学杂志 ›› 2015, Vol. 42 ›› Issue (5): 385-387.doi: 10.3760/cma.j.issn.1673422X.2015.05.018

非小细胞肺癌二线治疗的进展

汕头大学医学院附属肿瘤医院肿瘤内科

出版日期:2015-05-08 发布日期:2015-05-12
通讯作者: 王鸿彪 wanghongbiao123@qq.com

Second line treatment of nonsmall cell lung cancer

Department of Medical Oncology, Affiliated Cancer Hospital of Shantou University Medical College

Online:2015-05-08 Published:2015-05-12
Contact: Wang Hongbiao wanghongbiao123@qq.com

摘要/Abstract

摘要： 晚期非小细胞肺癌（NSCLC）二线标准治疗药物包括细胞毒药物培美曲塞和多西他赛，表皮生长因子酪氨酸激酶抑制剂厄洛替尼和吉非替尼。对于表皮生长因子受体基因野生型患者，研究提示化疗优于靶向治疗。在标准治疗药物基础上联合其他靶向治疗结果乏善可陈。克唑替尼针对间变性淋巴瘤激酶阳性的NSCLC患者二线治疗疗效显著。

Abstract: The cytotoxic agents pemetrexed and docetaxel and the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib are standard secondline therapies for nonsmall cell lung cancer. For patients without the EGFR mutation, more and more evidence has suggested the superiority of chemotherapy over targeted therapy. Adding targeted agents to standard secondline treatment is an trend of exploration, but without promising results nowadays. Crizotinib, targeting at anaplastic lymphoma kinase, has been shown excellent efficacy for secondline therapy in nonsmall cell lung cancer.

徐绮腻, 李绪渊, 王鸿彪. 非小细胞肺癌二线治疗的进展[J]. 国际肿瘤学杂志, 2015, 42(5): 385-387.

XU Qi-Ni, LI Xu-Yuan, WANG Hong-Biao. Second line treatment of nonsmall cell lung cancer[J]. Journal of International Oncology, 2015, 42(5): 385-387.

参考文献

［1］ Kawaguchi T, Ando M, Asami K, et al. Randomized phase Ⅲ trial of erlotinib versus docetaxel as second or thirdline therapy in patients with advanced nonsmallcell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA) ［J］. J Clin Oncol, 2014, 32(18):19021928. ［2］ Garassino MC, Martelli O, Broggini M, et al. Erlotinib versus docetaxel as secondline treatment of patients with advanced nonsmallcell lung cancer and wildtype EGFR tumours (TAILOR): a randomised controlled trial［J］. Lancet Oncol, 2013, 14(10): 981988. ［3］ Minami S1, Kijima T, Hamaguchi M, et al. Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced nonsquamous nonsmall cell lung cancer with documentation of epidermal growth factor receptor mutation status［J］. Lung Cancer, 2013, 82(2)： 271275. ［4］ Dittrich C, PapaiSzekely Z, Vinolas N, et al. A randomised phase Ⅱ study of pemetrexed versus pemetrexed+erlotinib as secondline treatment for locally advanced or metastatic nonsquamous nonsmall cell lung cancer［J］. Eur J Cancer, 2014, 50(9)： 15711580. ［5］ Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for secondline treatment of stage IV nonsmallcell lung cancer after disease progression on platinumbased therapy (REVEL)： a multicentre, doubleblind, randomised phase 3 trial［J］. Lancet, 2014, 384(9944)： 665673. ［6］ Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated nonsmallcell lung cancer (LUMELung 1)： a phase 3, doubleblind, randomised controlled trial［J］. Lancet Oncol, 2014, 15(2)： 143155. ［7］ Jnne PA, Shaw AT, Pereira JR, et al. Selumetinib plus docetaxel for KRASmutant advanced nonsmallcell lung cancer： a randomised, multicentre, placebocontrolled, phase 2 study［J］. Lancet Oncol, 2013, 14(1)： 3847. ［8］ Ramlau R, Gorbunova V, Ciuleanu TE, et al. Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic nonsmallcell lung cancer： a randomized, controlled phase Ⅲ trial［J］. J Clin Oncol, 2012, 30(29)： 36403647. ［9］ Kim ES, Neubauer M, Cohn A, et al. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive nonsmallcell lung cancer after platinumbased therapy： a phase 3, openlabel, randomised trial［J］. Lancet Oncol, 2013, 14(13)： 13261336. ［10］ Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALKpositive lung cancer［J］. N Engl J Med, 2013, 368(25)： 23852394. ［11］ Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALKrearranged nonsmallcell lung cancer［J］. N Engl J Med, 2014, 370(13)： 11891197. ［12］ Groen HJ, Socinski MA, Grossi F, et al. A randomized, doubleblind, phase II study of erlotinib with or without sunitinib for the secondline treatment of metastatic nonsmallcell lung cancer (NSCLC) ［J］. Ann Oncol, 2013, 24(9)： 23822389. ［13］ Ramalingam SS, Owonikoko TK, Behera M, et al. Phase Ⅱ study of docetaxel in combination with everolimus for secondor thirdline therapy of advanced nonsmallcell lung cancer［J］. J Thorac Oncol, 2013, 8(3)： 369372. ［14］ Papadimitrakopoulou VA, Soria JC, Jappe A, et al. Everolimus and erlotinib as second or thirdline therapy in patients with advanced nonsmallcell lung cancer［J］. J Thorac Oncol, 2012, 7(10)： 15941601.

非小细胞肺癌二线治疗的进展

Second line treatment of nonsmall cell lung cancer

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 0

编辑推荐

Metrics

本文评价